Skip to main content
SpringerLink
Log in
Book cover

Small Molecules in Oncology pp 27–65Cite as

Dasatinib

  • Chapter
  • First Online:

Part of the book series: Recent Results in Cancer Research ((RECENTCANCER,volume 201))

Abstract

Dasatinib is an orally available short-acting dual ABL/SRC tyrosine kinase inhibitor (TKI). It potently inhibits BCR-ABL and SRC family kinases (SRC, LCK, YES, FYN), but also c-KIT, PDGFR-α and PDGFR-β, and ephrin receptor kinase. Dasatinib is an effective treatment for chronic myeloid leukemia (CML) and Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL). Both diseases are characterized by a constitutively active tyrosine kinase; BCR-ABL. Dasatinib inhibits BCR-ABL with greater potency compared with other BCR-ABL inhibitors and is active in CML resistant or intolerant to imatinib. Dasatinib is approved for the treatment of CML (all phases) and for the treatment of Ph+ ALL, resistant or intolerant to prior imatinib treatment. Randomized trial data in CML show that first-line dasatinib provides superior responses compared with imatinib and enables patients to achieve early, deep responses, correlated with improved longer-term outcomes. A once-daily dose of 100 mg in chronic phase CML results in high hematologic and molecular remission rates and prolongation of survival. In accelerated and blastic phase of CML, as well as in Ph+ ALL, complete hematologic and cytogenetic remissions frequently occur. Remissions however are very short. In these patients, once-daily 140 mg is the recommended dose. The effect of dasatinib in other malignancies including solid tumors is subject of clinical studies. Regardless of many clinical trials in different tumor types and in different combinations of dasatinib with other agents, the role of dasatinib in the treatment of solid tumors has not yet been defined. Side effects of dasatinib are frequent but mostly moderate and manageable and include cytopenias and pleural effusions. The review presents the preclinical and clinical activity of dasatinib with a focus on clinical studies in CML.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   139.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  • Algazi AP, Weber JS, Andrews SC (2012) Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma. Br J Cancer 106:85–91

    CAS  PubMed Central  PubMed  Google Scholar 

  • Amrein L, Hernandez TA, Ferrario C et al (2008) Dasatinib sensitizes primary chronic lymphocytic leukaemia lymphocytes to chlorambucil and fludarabine in vitro. Br J Haematol 143:698–706

    CAS  PubMed  Google Scholar 

  • Amrein PC, Attar EC, Takvorian T et al (2011) Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemia. Clin Cancer Res 17:2977–2986

    CAS  PubMed Central  PubMed  Google Scholar 

  • Apperley JF, Cortes JE, Kim DW et al (2009) Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial. J Clin Oncol 27:3472–3479

    CAS  PubMed  Google Scholar 

  • Araujo J, Armstrong AJ, Braud EL et al (2009) Dasatinib and docetaxel combination treatment for patients with castration-resistant progressive prostate cancer: a phase I/II study (CA180086). J Clin Oncol 27(Suppl):5061

    Google Scholar 

  • Araujo J, Mathew P, Armstrong AJ et al (2012) Dasatinib combined with docetaxel for castration-resistant prostate cancer. Results from a phase 1-2 study. Cancer 118:63–71

    CAS  PubMed Central  PubMed  Google Scholar 

  • Araujo J, Trudel GC, Saad F et al (2013) Overall survival (OS) and safety of dasatinib/docetaxel versus docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC): results from the randomized phase III READY trial. J Clin Oncol 31(Suppl 6):abstract LBA8

    Google Scholar 

  • Baccarani M, Deininger MW, Rosti G et al (2013) European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122:872–884

    CAS  PubMed  Google Scholar 

  • Bild AH, Yao G, Chang JT et al (2006) Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439:353–357

    CAS  PubMed  Google Scholar 

  • Baccarani M, Rosti G, Saglio G et al (2008) Dasatinib time to and durability of major and complete cytogenetic response (MCyR and CCyR) in patients with chronic myeloid leukemia in chronic phase (CML-CP). Blood 112(Suppl):450

    Google Scholar 

  • Bocchia M, Defina M, Ippoliti M et al (2010) Evaluation of residual CD34+/Ph+ stem cells in chronic myeloid leukemia patients in complete cytogenetic response during first line nilotinib therapy. Blood 116:1398

    Google Scholar 

  • Branford S, Melo JV, Hughes TP (2009) Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter? Blood 114:5426–5435

    CAS  PubMed  Google Scholar 

  • Brooks HD, Glisson BS, Bekele BN et al (2011) Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma. Cancer 117:2112–2119

    CAS  PubMed Central  PubMed  Google Scholar 

  • Bullinger L, Döhner K, Bair E et al (2004) Use of gene expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. New Engl J Med 350:1605–1616

    CAS  PubMed  Google Scholar 

  • Byrd JC, Furman RR, Coutre SE et al (2013) Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 369:32–42

    CAS  PubMed Central  PubMed  Google Scholar 

  • Chang Q, Jorgensen C, Pawson T, Hedley DW (2008) Effects of dasatinib on EphA2 receptor tyrosine kinase activity and downstream signaling in pancreatic cancer. Br J Cancer 99:1074–1082

    CAS  PubMed Central  PubMed  Google Scholar 

  • Chen Z, Lee FY, Bhalla KN et al (2006) Potent inhibition of platelet-derived growth factor-induced responses in vascular smooth muscle cells by BMS-354825 (Dasatinib). Mol Pharmacol 69:1527–1533

    CAS  PubMed  Google Scholar 

  • Cortes J, Jabbour E, Kantarjian H et al (2007a) Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors. Blood 110:4005–4011

    CAS  PubMed  Google Scholar 

  • Cortes J, Kim DW, Raffoux E et al (2008) Efficacy and safety of dasatinib in imatinib-resistant or intolerant patients with chronic myeloid leukemia in blast phase. Leukemia 22:2176–2183

    CAS  PubMed  Google Scholar 

  • Cortes J, Rousselot P, Kim DW et al (2007b) Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or—intolerant chronic myeloid leukemia in blast crisis. Blood 109:3207–3213

    CAS  PubMed  Google Scholar 

  • Cortes J, Talpaz M, Bixby D et al (2010a) A phase 1 trial of oral ponatinib (AP24534) in patients with refractory chronic myelogenous leukemia (CML) and other hematologic malignancies: Emerging safety and clinical response findings. Blood 116(suppl) (abs 210)

    Google Scholar 

  • Cortes JE, Jones D, O’Brien S et al (2010b) Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia. J Clin Oncol 28:398–404

    CAS  PubMed Central  PubMed  Google Scholar 

  • Cross NCP, Reiter A (2008) Fibroblast growth factor receptor and platelet-derived growth factor receptor abnormalities in eosinophilic myeloproliferative disorders. Acta Haematol 119:199–206

    CAS  PubMed  Google Scholar 

  • Das J, Chen P, Norris D et al (2006) 2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (dasatinib, BMS-354825) as a potent pan-Src kinase inhibitor. J Med Chem 49:6819–6832

    CAS  PubMed  Google Scholar 

  • Dewaele B, Floris G, Finalet-Ferreiro J et al (2010) Coactivated platelet-derived growth factor receptor alpha and epidermal growth factor receptor are potential therapeutic targets in intimal sarcoma. Cancer Res 70:7304–7314

    CAS  PubMed  Google Scholar 

  • Donato NJ, Wu JY, Stapley G et al (2003) BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to ST571. Blood 101:690–698

    CAS  PubMed  Google Scholar 

  • Dos Santos C, McDonald T, Ho YW et al (2013) The Src and c-Kit kinase inhibitor dasatinib enhances p53-mediated targeting of human acute myeloid leukemia stem cell by chemotherapeutic agents. Blood. July 29 (Epub ahead of print)

    Google Scholar 

  • Dudek AZ, Pang H, Kratzke RA et al (2012) Phase II study of dasatinib in patients with previously treated malignant mesothelioma (cancer and leukemia group B 30601): a brief report. J Thorac Oncol 7:755–759

    CAS  PubMed Central  PubMed  Google Scholar 

  • Dumitrescu D, Seck C, Ten FH et al (2011) Fully reversible pulmonary arterial hypertension associated with dasatinib treatment for chronic myeloid leukaemia. Eur Respir J 38:218–220

    CAS  PubMed  Google Scholar 

  • Duong VH, Jaglal MV, Zhang L et al (2008) Phase II pilot study of oral dasatinib in patients with higher-risk myelodysplastic syndrome (MDS) who failed conventional therapy. Blood 112(Suppl) (abstract 4197)

    Google Scholar 

  • European Medicines Agency (2012) Sprycel (dasatinib) summary of product characteristics. Uxbridge, UK, Bristol-Myers Squibb Pharma EEIG. Nov 2012. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000709/WC500056998.pdf

  • Fabarius A, Giehl M, Rebacz B et al (2008) Centrosome aberrations and G1 phase arrest after in vitro and in vivo treatment with the SRC/ABL inhibitor dasatinib. Haematologica 93:1145–1154

    CAS  PubMed  Google Scholar 

  • Fang JC, DeMarco T, Givertz MM et al (2012) World Health Organization pulmonary hypertension group 2: pulmonary hypertension due to left heart disease in the adult–a summary statement from the pulmonary hypertension council of the international society for heart and lung transplantation. J Heart Lung Transplant 31:913–933

    PubMed  Google Scholar 

  • Finn RS, Dering J, Ginther C et al (2007) Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/“triple-negative” breast cancer cell lines growing in vitro. Breast Cancer Res Treat 105:319–326

    CAS  PubMed  Google Scholar 

  • Finn RS, Bengala C, Ibrahim N et al (2011) Dasatinib as a single agent in triple-negative breast cancer: results of an open-label phase 2 study. Clin Cancer Res 17(21):6905–6913

    CAS  PubMed  Google Scholar 

  • Flaherty KD, Robert C, Hersey P et al (2012) Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 367:107–114

    CAS  PubMed  Google Scholar 

  • Foa R, Vitale A, Vignetti M et al (2011) Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 118:6521–6528

    CAS  PubMed  Google Scholar 

  • Fornier MN, Morris PG, Abbruzzi A et al (2011) A phase I study of dasatinib and weekly paclitaxel for metastatic breast cancer. Ann Oncol 22:2575–2581

    CAS  PubMed  Google Scholar 

  • Franceschi E, Stupp R, van den Bent MJ et al (2012) EORTC 26083 phase I/II trial of dasatinib in combination with CCNU in patients with recurrent glioblastoma. Neuro Oncol 14:1503–1510

    CAS  PubMed Central  PubMed  Google Scholar 

  • Galie N, Hoeper MM, Humbert M et al (2009) Guidelines for the diagnosis and treatment of pulmonary hypertension: the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 30:2493–2537; Eur Respir J 34:1219–1263

    Google Scholar 

  • Garcia-Gomez A, Ocio EM, Crusoe E et al (2012) Dasatinib as a bone-modifying agent: anabolic and anti-resorptive effects. PLoS ONE 7(4):e34914

    CAS  PubMed Central  PubMed  Google Scholar 

  • Garg RJ, Wierda W, Fayad L et al (2008) Phase II study of dasatinib in patients with relapsed CLL abstract. Blood 112(Suppl) (abstract 4197)

    Google Scholar 

  • Guilhot F, Apperley J, Kim D-W et al (2007a) Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or—intolerant chronic myeloid leukemia in accelerated phase. Blood 109:4143–4150

    CAS  PubMed  Google Scholar 

  • Guilhot F, Apperley JF, Kim DW et al (2007b) Efficacy of dasatinib in patients with. Accelerated-phase chronic myelogenous leukemia with resistance or intolerance to imatinib: 2-year follow-up data from START-A (CA180-005). Blood 110(Suppl) (abstract 470)

    Google Scholar 

  • Guilhot F, Kantarjian H, Shah NP et al (2010) Dasatinib (versus imatinib) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): analysis of safety and efficacy by use of baseline medications in the DASISION trial. Blood 116(Suppl) (abstract 2295)

    Google Scholar 

  • Hallaert DYH, Jaspers A, van Noesel CJ et al (2008) c-Abl kinase inhibitors overcome CD40-mediated drug resistance in CLL: implications for therapeutic targeting of chemoresistant niches. Blood 112:5141–5149

    CAS  PubMed  Google Scholar 

  • Hanfstein B, Muller MC, Hehlman R et al (2012) Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia 26:2096–2102

    CAS  PubMed  Google Scholar 

  • Hantschel O, Rix U, Schmidt U et al (2007) The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib. Proc Natl Acad Sci USA 104:13283–13288

    CAS  PubMed Central  PubMed  Google Scholar 

  • Haura EB, Tanvetyanon T, Chiappori A et al (2010) Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer. J Clin Oncol 28:1387–1394

    CAS  PubMed Central  PubMed  Google Scholar 

  • Hehlmann R, Hochhaus A, Baccarani M (2007) Chronic myeloid leukaemia. Lancet 370:342–350

    CAS  PubMed  Google Scholar 

  • Heinrich MC, Corless CL, Duensing A et al (2003) PDGFRA activating mutations in gastrointestinal stromal tumors. Science 299:708–710

    CAS  PubMed  Google Scholar 

  • Heldin CH, Westermark B (1999) Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 79:1283–1316

    CAS  PubMed  Google Scholar 

  • Hennigs JK, Keller G, Baumann HJ et al (2011) Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension? BMC Pulm Med 11:30

    CAS  PubMed Central  PubMed  Google Scholar 

  • Hirota S, Isozaki K, Moriyama Y et al (1998) Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279:577–580

    CAS  PubMed  Google Scholar 

  • Hiwase DK, White DL, Powell JA et al (2010) Blocking cytokine signaling along with intense Bcr-Abl kinase inhibition induces apoptosis in primary CML progenitors. Leukemia 24:771–778

    CAS  PubMed  Google Scholar 

  • Hochhaus A, Baccarani M, Deininger M et al (2008) Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia 22:1200–1206

    CAS  PubMed  Google Scholar 

  • Hochhaus A, Boqué C, Bradley Garelik MB et al (2012b) Molecular response kinetics and BCR-ABL reductions in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) receiving dasatinib versus imatinib: DASISION 3-year follow-up. Haematologica 97(Suppl 1) (abstract 1537)

    Google Scholar 

  • Hochhaus A, Kantarjian HM (2013) The development of dasatinib as a treatment for chronic myeloid leukemia (CML): from initial studies to application in newly diagnosed patients. J Cancer Res Clin Oncol. Aug 13 (Epub ahead of print)

    Google Scholar 

  • Hochhaus A, Kantarjian HM, Baccarani M et al (2007) Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood 109:2303–2309

    CAS  PubMed  Google Scholar 

  • Hochhaus A, Shah NP, Cortes JE et al (2012a) Dasatinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): DASISION 3-year follow-up. J Clin Oncol 30(Suppl) (abstract 6504)

    Google Scholar 

  • Huang F, Reeves K, Han X et al (2007) Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection. Cancer Res 67:2226–2238

    CAS  PubMed  Google Scholar 

  • Imagawa J, Harada Y, Yoshida T et al (2011) Successful treatment with low-dose dasatinib in a patient with chronic eosinophilic leukemia intolerant to imatinib. Rinsho Ketsueki 52:546–550

    PubMed  Google Scholar 

  • Jabbour E, Kantarjian HM, Quintás-Cardama A et al (2011) Impact of dose reductions and interruptions due to adverse events (AEs) on efficacy in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) patients (pts) receiving either dasatinib (D) or imatinib (IM): analysis of the DASISION trial. Blood 118(Suppl) (abstract 2768)

    Google Scholar 

  • Johnson FM, Agrawal S, Burris H et al (2010) Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumors. Cancer 116:1582–1591

    CAS  PubMed  Google Scholar 

  • Johnson FM, Saigal B, Talpaz M et al (2005) Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells. Clin Cancer Res 11:6924–6932

    CAS  PubMed  Google Scholar 

  • Johnson ML, Riely GJ, Rizvi NA et al (2011) Phase II trial of dasatinib for patients with acquired resistance to treatment with the epidermal growth factor receptor tyrosine kinase inhibitors erlotinib or gefitinib. J Thorac Oncol 6:1128–1131

    PubMed Central  PubMed  Google Scholar 

  • Kantarjian H, Cortes J, Kim D-W et al (2009a) Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up. Blood 113:6322–6329

    CAS  PubMed  Google Scholar 

  • Kantarjian H, Pasquini R, Levy V et al (2009b) Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R). Cancer 115:3935–3942

    PubMed  Google Scholar 

  • Kantarjian H, Pasquini R, Lévy V et al (2009c) Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily. Cancer 115:4136–4147

    CAS  PubMed  Google Scholar 

  • Kantarjian H, Shah NP, Hochhaus A et al (2010) Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 362:2260–2270

    CAS  PubMed  Google Scholar 

  • Kantarjian HM, Pasquini R, Hamerschlak N et al (2007) Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood 109:5143–5150

    CAS  PubMed  Google Scholar 

  • Kantarjian HM, Shah NP, Cortes JE et al (2012) Dasatinib or imatinib in newly diagnosed chronic phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood 119:1123–1129

    CAS  PubMed  Google Scholar 

  • Karaman MW, Herrgard S, Treiber DK et al (2008) A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 26:127–132

    CAS  PubMed  Google Scholar 

  • Khoury HJ, Cortes JE, Kantarjian H et al (2010) Safety and efficacy of dasatinib (DAS) versus imatinib (IM) by baseline comorbidity in patients with chronic myeloid leukemia in chronic phase (CML-CP): analysis of the DASISION trial. Blood 116(Suppl) (abstract 3421)

    Google Scholar 

  • Kluger HM, Dudek AZ, McCann C et al (2011) A phase 2 trial of dasatinib in advanced melanoma. Cancer 117:2202–2208

    CAS  PubMed Central  PubMed  Google Scholar 

  • Kopetz S, Shah AN, Gallick GE (2007) Src continues aging: Current and future clinical directions. Clin Cancer Res 13:7232–7236

    CAS  PubMed  Google Scholar 

  • Kreutzman A, Juvonen V, Kairisto V et al (2010) Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy. Blood 116:772–782

    CAS  PubMed  Google Scholar 

  • Kreutzman A, Ladell K, Koechel C et al (2011) Expansion of highly differentiated CD8þ T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation. Leukemia 25:1587–1597

    CAS  PubMed  Google Scholar 

  • Kullander K, Klein R (2002) Mechanisms and functions of Eph and ephrin signalling. Nat Rev Mol Cell Biol 3:475–486

    CAS  PubMed  Google Scholar 

  • La Rosée P, Martiat P, Leitner, A et al (2013) Improved tolerability by a modified intermittent treatment schedule of dasatinib for patients with chronic myeloid leukemia resistant or intolerant to imatinib. Ann Hematol. April 28 (Epub ahead of print)

    Google Scholar 

  • Laneuville P, Baccarani M, Cortes J et al (2011) Analysis of patients (pts) with chronic-phase chronic myeloid leukemia (CML-CP) who develop pleural effusion on first-line dasatinib: management and outcomes. J Clin Oncol 29(Suppl) (abstract 6605)

    Google Scholar 

  • Levinson NM, Boxer SG (2012) Structural and spectroscopic analysis of the kinase inhibitor bosutinib and an isomer of bosutinib binding to the Abl Tyrosine Kinase Domain. PLoS One 7:e29828

    CAS  PubMed Central  PubMed  Google Scholar 

  • Li C, Lida M, Dunn EF et al (2009) Nuclear EGFR contributes to acquired resistance to cetuximab. Oncogene 28:3801–3813

    CAS  PubMed Central  PubMed  Google Scholar 

  • Lombardo LJ, Francis YL, Chen P et al (2004) Discover of N-(2-Chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 47:6658–6661

    CAS  PubMed  Google Scholar 

  • Marin D, Hedgley C, Clark RE et al (2012) The predictive value of early molecular response in chronic phase CML patients treated with dasatinib first line therapy. Blood 120:291–294

    CAS  PubMed  Google Scholar 

  • Mattei D, Feola M, Orzan F et al (2009) Reversible dasatinib-induced pulmonary arterial hypertension and right ventricle failure in a previously allografted CML patient. Bone Marrow Transplant 43:967–968

    CAS  PubMed  Google Scholar 

  • Mauro MJ, Baccarani M, Cervantes F et al (2008) Dasatinib 2-year efficacy in patients with chronic-phase chronic myelogenous leukemia (CML-CP) with resistance or intolerance to imatinib (START-C). J Clin Oncol 26(Suppl) (abstract 7009)

    Google Scholar 

  • Mayer EL, Krop IE (2010) Advances in targeting Src in the treatment of breast cancer and other solid malignancies. Clin Cancer Res 16:3526–3532

    CAS  PubMed  Google Scholar 

  • Mayer EL, Baurain JF, Sparano J et al (2011) A phase 2 trial of dasatinib in patients with advanced HER2-positive and/or hormone receptor-positive breast cancer. Clin Cancer Res 17(21):6897–6904

    CAS  PubMed  Google Scholar 

  • McLaughlin VV, Archer SL, Badesch DB et al (2009) ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation task force on expert consensus documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol 53:1573–1619; Circulation 119:2250–2294

    Google Scholar 

  • Metcalf CA 3rd, van Schravendijk MR, Dalgarno DC, Sawyer TK (2002) Targeting protein kinases for bone disease: discovery and development of Src inhibitors. Curr Pharm Des 8:2049–2075

    CAS  PubMed  Google Scholar 

  • Miller AA, Pang H, Hodgson L et al (2010) A phase II study of dasatinib in patients with chemosensitive relapsed small cell lung cancer (Cancer and Leukemia Group B 30602). J Thorac Oncol 5:380–384

    PubMed Central  PubMed  Google Scholar 

  • Montani D, Bergot E, Gunther S (2012) Pulmonary arterial hypertension in patients treated by dasatinib. Circulation 125:2128–2137

    CAS  PubMed  Google Scholar 

  • Montero JS, Seoane S, Ocaña A et al (2011) Inhibition of Src family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors. Clin Cancer Res 17:5546–5552

    CAS  PubMed  Google Scholar 

  • Moulder S, Yan K, Huang F et al (2010) Development of candidate genomic markers to select breast cancer patients for dasatinib therapy. Mol Cancer Ther 9:1120–1127

    CAS  PubMed  Google Scholar 

  • Müller MC, Cortes JE, Kim DW et al (2009) Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations. Blood 114:4944–4953

    PubMed  Google Scholar 

  • Mustjoki S, Auvinen K, Kreutzman A et al (2013) Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy. Leukemia 27:914–924

    CAS  PubMed  Google Scholar 

  • Mustjoki S, Richter J, Barbany G et al (2011) Favorable therapeutic responses in newly diagnosed CML-CP patients induced by dasatinib are reflected at the CD34+CD38+ progenitor cell but not at the CD34+CD38—stem cell level: results from randomized NordCML006 study. Blood 118(Suppl) (abstract 784)

    Google Scholar 

  • Mustjoki S, Rousselot P, Jalkanen S et al (2010) Dasatinib induces a rapid, dose-controllable mobilization of cytotoxic lymphocytes: a novel immunomodulatory effect associated with prolonged therapy responses in advanced leukemia. Blood 116(Suppl) (abstract 1204)

    Google Scholar 

  • Nam S, Kim D, Cheng JQ et al (2005) Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res 65:9185–9189

    CAS  PubMed  Google Scholar 

  • National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology™. Chronic myelogenous leukemia v.4.2013. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site

  • Neelakantan P, Gerrard G, Lucas C et al (2013) Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies. Blood 121:2739–2742

    CAS  PubMed  Google Scholar 

  • O’Hare T, Shakespeare WC, Zhu X et al (2009) AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 16:401–412

    PubMed Central  PubMed  Google Scholar 

  • O’Hare T, Walters DK, Stoffregen EP et al (2005) In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 65:4500–4505

    PubMed  Google Scholar 

  • Orlandi EM, Rocca B, Pazzano AS et al (2011) Reversible pulmonary arterial hypertension likely related to long-term, low-dose dasatinib treatment for chronic myeloid leukaemia. Leuk Res 36(1):e4–e6

    PubMed  Google Scholar 

  • Ottmann O, Dombret H, Martinelli G et al (2007) Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. Blood 110:2309–2315

    CAS  PubMed  Google Scholar 

  • Pan Z, Scheerens H, Li SJ et al (2007) Discovery of selective irreversible inhibitors for Bruton’s tyrosine kinase. ChemMedChem 2:58–61

    CAS  PubMed  Google Scholar 

  • Park SI, Zhang JZ, Phillips KA et al (2008) Targeting Src family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model. Cancer Res 68:3323–3333

    CAS  PubMed  Google Scholar 

  • Pemmaraju N, Kantarjian H, Luthra R et al (2011) Results of a phase II trial of dasatinib as frontline therapy for chronic myeloid leukemia (CML) in chronic phase (CP). Blood 118(Suppl) (abstract 1700)

    Google Scholar 

  • Pene-Dumitrescu T, Smithall TE (2010) Expression of a Src family kinase in chronic myelogenous leukemia cells induces resistance to imatinib in a kinase-dependent manner. J Biol Chem 285:21446–21457

    CAS  PubMed Central  PubMed  Google Scholar 

  • Philibert L, Carzola C, Peyriere H et al (2011) Pulmonary arterial hypertension induced by dasatinib: positive reintroduction with nilotinib. Fundam Clin Pharmacol 25(Suppl):95 (abstract 476)

    Google Scholar 

  • Pittini V, Arrigo C, Altavilla G. et al (2009) Dasatinib induces a response in chronic lymphocytic leukemia. Blood 113(Suppl) (abstract 498)

    Google Scholar 

  • Porkka K, Khoury HJ, Paquette RL et al (2010) Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy in unaffected in patients who develop pleural effusion. Cancer 116:377–386

    CAS  PubMed  Google Scholar 

  • Porkka K, Koskenvesa P, Lundan T et al (2008) Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome–positive leukaemia. Blood 112:1005–1012

    CAS  PubMed  Google Scholar 

  • Porkka K, Simonsson B, Dombret H et al (2007) Efficacy of dasatinib in patients with Philadelphia-chromosome-positive acute lymphoblastic leukemia who are resistant or intolerant to imatinib: 2-year follow-up data from START-L (CA180-015). Blood 110(Suppl) (abstract 2810)

    Google Scholar 

  • Quintás-Cardama A, Kantarjian H, O’Brien S et al (2007) Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol 25:3908–3914

    PubMed  Google Scholar 

  • Quintás-Cardama A, Kantarjian H, Ravandi F et al (2009) Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy. Cancer 115:2482–2490

    PubMed  Google Scholar 

  • Radich JP, Kopecky KJ, Applebaum FR et al (2012) A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic phase chronic myeloid leukemia in chronic phase (CML-CP). Blood 120:3898–3905

    CAS  PubMed Central  PubMed  Google Scholar 

  • Rasheed W, Flaim B, Seymour JF (2009) Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemia. Leuk Res 33:861–864

    PubMed  Google Scholar 

  • Ravandi F, O’Brien S, Thomas D et al (2010) First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia. Blood 116:2070–2077

    CAS  PubMed  Google Scholar 

  • Rea D, Vellenga E, Junghan C et al (2012) Six-year follow-up of patients with imatinib-resistant or imatinib-intolerant chronic phase chronic myeloid leukemia (CML-CP) receiving dasatinib. Haematologica 97(Suppl 1) (abstract 199)

    Google Scholar 

  • Reardon DA, Vredenburgh JJ, Desjardins A et al (2012) Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma. J Neurooncol 108:499–506

    CAS  PubMed Central  PubMed  Google Scholar 

  • Redaelli S, Piazza R, Rostagno R et al (2009) Activity of bosutinib, dasatinib and nilotinib against 18 imatinib-resistant BCR/ABL mutants. J Clin Oncol 27:469–471

    CAS  PubMed  Google Scholar 

  • Ren CL, Morio T, Fu SM, Geha RS (1994) Signal transduction via CD40 involves activation of lyn kinase and phosphatidylinositol-3-kinase, and phosphorylation of phospholipase C gamma 2. J Exp Med 179:673–680

    CAS  PubMed  Google Scholar 

  • Rousselot P, Boucher S, Etienne G et al (2010) Pharmacokinetics of dasatinib as a first line therapy in newly diagnosed CML patients (OPTIM dasatinib trial): correlation with safety and response. Blood 116(Suppl) (abstract 3432)

    Google Scholar 

  • Rousselot P, Mollica L, Etienne G et al (2012) Pharmacologic monitoring of dasatinib as first line therapy in newly diagnosed chronic phase chronic myelogenous leukemia (CP-CML) identifies patients at higher risk of pleural effusion: a sub-analysis of the OPTIM-dasatinib trial. Blood 120(Suppl) (abstract 3770)

    Google Scholar 

  • Saglio G, Dombret H, Rea D et al (2008) Dasatinib efficacy in patients with imatinib-resistant/-intolerant chronic myeloid leukemia in blast phase: 24-month data from the START program. Haematologica 93 (abstract 0880)

    Google Scholar 

  • Saglio G, Hochhaus A, Cortes JE et al (2010c) Safety and efficacy of dasatinib versus imatinib by baseline cardiovascular comorbidity in patients with chronic myeloid leukemia in chronic phase (CML-CP): analysis of the DASISION trial. Blood 116(Suppl) (abstract 2286)

    Google Scholar 

  • Saglio G, Hochhaus A, Goh YT et al (2010) Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study. Cancer 116:3852–3861

    CAS  PubMed  Google Scholar 

  • Saglio G, Kantarjian HM, Shah N et al (2012) Early response (molecular and cytogenetic) and long-term outcomes in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): exploratory analysis of DASISION 3-year data. Blood 120(Suppl) (abstract 1675)

    Google Scholar 

  • Sano M, Saotome M, Urushida T et al (2012) Pulmonary arterial hypertension caused by treatment with dasatinib for chronic myeloid leukemia: critical alert. Intern Med 51:2337–2340

    CAS  PubMed  Google Scholar 

  • Schiffer CA, Cortes JE, Saglio G et al (2010a) Lymphocytosis following first-line treatment for CML in chronic phase with dasatinib is associated with improved responses: a comparison with imatinib. Blood 116(Suppl) (abstract 358)

    Google Scholar 

  • Schiffer CA, Cortes JE, Saglio G et al (2010b) Lymphocytosis following treatment with dasatinib is associated with improved response and outcome. J Clin Oncol 28:15s (abstract 6553)

    Google Scholar 

  • Schittenhelm MM, Shiraga S, Schroeder A et al (2006) Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res 66:473–481

    CAS  PubMed  Google Scholar 

  • Schilder RJ, Brady WE, Lankes HA et al (2012) Phase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a gynecologic oncology group (GOG) trial. Gynecol Oncol 127:70–74

    CAS  PubMed Central  PubMed  Google Scholar 

  • Secord AA, Teoh DK, Barry WT et al (2012) A phase I trial of dasatinib, an SRC-family kinase inhibitor, in combination with paclitaxel and carboplatin in patients with advanced or recurrent ovarian cancer. Clin Cancer Res 18:5489–5498

    CAS  PubMed Central  PubMed  Google Scholar 

  • Serrels A, Macpherson IRJ, Evans TRJ et al (2006) Identification of potential biomarkers for measuring inhibition of Src kinase activity in colon cancer cells following treatment with dasatinib. Mol Cancer Ther 5:3014–3022

    CAS  PubMed  Google Scholar 

  • Shah NP, Kantarjian H, Kim DW et al (2012) Six-year follow-up of patients with imatinib-resistant or—intolerant chronic-phase chronic myeloid leukemia receiving dasatinib. J Clin Oncol 30(Suppl) (abstract 6506)

    Google Scholar 

  • Shah NP, Kantarjian HM, Kim DW et al (2008a) Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and—intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol 26:3204–3212

    CAS  PubMed  Google Scholar 

  • Shah NP, Kasap C, Weier C et al (2008b) Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis. Cancer Cell 14:485–493

    CAS  PubMed  Google Scholar 

  • Shah NP, Kim DW, Kantarjian H et al (2010) Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib. Haematologica 95:232–240

    CAS  PubMed Central  PubMed  Google Scholar 

  • Shah NP, Lee FY, Luo R et al (2006) Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis. Blood 108:286–291

    CAS  PubMed  Google Scholar 

  • Shah NP, Skaggs BJ, Branford S et al (2007) Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. J Clin Invest 117:2562–2569

    CAS  PubMed Central  PubMed  Google Scholar 

  • Shah NP, Tran C, Lee FY et al (2004) Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305:399–401

    CAS  PubMed  Google Scholar 

  • Sharma MR, Wroblewski K, Polite BN et al (2012) Dasatinib in previously treated metastatic colorectal cancer: a phase II trial of the University of Chicago Phase II Consortium. Invest New Drugs 30:1211–1215

    CAS  PubMed  Google Scholar 

  • Shor AC, Keschman EA, Lee FY et al (2007) Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on Src kinase for survival. Cancer Res 67:2800–2808

    CAS  PubMed  Google Scholar 

  • Smith CI, Islam TC, Mattsson PT et al (2001) The Tec family of cytoplasmic tyrosine kinases: mammalian Btk, Bmx, Itk, Tec, Txk and homologs in other species. BioEssays 23:436–446

    CAS  PubMed  Google Scholar 

  • Somlo G, Atzori F, Strauss LC et al (2013) Dasatinib plus capecitabine for advanced breast cancer: safety and efficacy in phase I study CA180004. Clin Cancer Res 19:1884–1893

    CAS  PubMed  Google Scholar 

  • Song Z, Lu P, Furman RR et al (2010) Activities of SYK and PLCg2 predict apoptotic response of CLL cells to SRC tyrosine kinase inhibitor dasatinib. Clin Cancer Res 16:587–599

    CAS  PubMed  Google Scholar 

  • Soverini S, Gnani A, Colarossi S et al (2009) Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors. Blood 114:2168–2171

    CAS  PubMed  Google Scholar 

  • Sprycel® (dasatinib) capsules prescribing information. Princeton, NJ, Bristol-Myers Squibb Company, Nov 2012. http://packageinserts.bms.com/pi/pi_sprycel.pdf

  • Starodub A, Cohn AL, Arrowood C et al (2011) Phase I study of dasatinib in combination with capecitabine, oxaliplatin, and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer. J Clin Oncol 29(Suppl) (abstract 513)

    Google Scholar 

  • Strickler JH, Cohn AL, Arrowood C et al (2011) Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer. J Clin Oncol 29(Suppl) (abstract 3586)

    Google Scholar 

  • Talpaz M, Shah NP, Kantarjian H et al (2006) Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 354:2531–2541

    CAS  PubMed  Google Scholar 

  • Tokarski JS, Newitt JA, Chang CY et al (2006) The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res 66:5790–5797

    CAS  PubMed  Google Scholar 

  • Ustun C, Corless CL, Savage N et al (2009) Chemotherapy and dasatinib induce long-term hematologic and molecular remission in systemic mastocytosis with acute myeloid leukemia with KIT D816V. Leuk Res 33:735–741

    CAS  PubMed  Google Scholar 

  • Vajpai N, Strauss A, Fendrich G et al (2008) Solution conformations and dynamics of ABL kinase-inhibitor complexes determined by NMR substantiate the different binding modes of imatinib/nilotinib and dasatinib. J Biol Chem 283:18292–18302

    CAS  PubMed  Google Scholar 

  • Van Cutsem E, Kohne C-H, Hitre E et al (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360:1408–1417

    PubMed  Google Scholar 

  • Verstovsek S, Tefferi A, Cortes J et al (2008) Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis. Clin Cancer Res 14:3907–3915

    Google Scholar 

  • Weisberg E, Manley PW, Breitenstein W et al (2005) Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 7:129–141

    CAS  PubMed  Google Scholar 

  • Wong S, Witte ON (2004) The BCR-ABL story: bench to bedside and back. Annu Rev Immunol 22:247–306

    CAS  PubMed  Google Scholar 

  • Zhou T, Commodore L, Huang W-S et al (2011) Structural mechanism of the pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance. Chem Biol Drug Des 77:1–11

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. III. Medizinische Klinik, Klinikum am Gesundbrunnen, Am Gesundbrunnen 20–24, 74078, Heilbronn, Germany

    Markus Lindauer

  2. Abteilung Hämatologie/Onkologie, Klinik für Innere Medizin II, Universitätsklinikum Jena, Erlanger Allee 101, 07740, Jena, Germany

    Andreas Hochhaus

Authors
  1. Markus Lindauer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andreas Hochhaus
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Markus Lindauer .

Editor information

Editors and Affiliations

  1. Cancer Center Heilbronn-Franken, SLK-Kliniken Heilbronn GmbH Medizinische Klinik III, Heilbronn, Germany

    Uwe M. Martens

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Lindauer, M., Hochhaus, A. (2014). Dasatinib. In: Martens, U. (eds) Small Molecules in Oncology. Recent Results in Cancer Research, vol 201. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-54490-3_2

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-54490-3_2

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-54489-7

  • Online ISBN: 978-3-642-54490-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation